Since its discovery in 2011, CRISPR-Cas 9 has revolutionized medicine. One of the companies at the forefront of this ...

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a ... with genetic redundancy and a lack of specificity in gene targeting. Here the authors develop a scalable ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

Crispr Therapeutics is an emerging gene editing company focused on the ... At the end of 2024, Crispr Therapeutics had $1.9 billion in cash and equivalents and marketable securities, which we ...

CRISPR-Cas systems are prokaryotic ... and a lack of specificity in gene targeting. Here the authors develop a scalable CRISPR system in tomato to edit multiple genes at once, overcoming genetic ...

In December 2020, the New England Journal of Medicine published a paper titled CRISPR-Cas9 Gene Editing for Sickle Cell Disease and ... Register now for free to discover the promise of CRISPR Cas 9 ...